Compare TRX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | ADAG |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | Canada | China |
| Employees | N/A | 128 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.1M | 222.2M |
| IPO Year | 2002 | 2020 |
| Metric | TRX | ADAG |
|---|---|---|
| Price | $1.29 | $2.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $1.70 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 3.1M | 197.3K |
| Earning Date | 04-15-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $84.84 | N/A |
| Revenue Next Year | $96.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.44 |
| 52 Week High | $2.80 | $4.85 |
| Indicator | TRX | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 58.74 | 33.30 |
| Support Level | $1.07 | $2.78 |
| Resistance Level | $2.00 | $3.19 |
| Average True Range (ATR) | 0.08 | 0.27 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 61.76 | 0.00 |
TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.